EcoDrugPlus

Janus Kinase 3

Ensembl ID : ENSANAG00000010485
Gene Symbol: JAK3
4 Cross references
103 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSANAG00000030367
Gene Symbol: KIT
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSANAG00000030296
Gene Symbol: KRAS
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSANAG00000034805
Gene Symbol: LCK
4 Cross references
120 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSANAG00000021085
Gene Symbol: LYN
4 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Malt1 Paracaspase

Ensembl ID : ENSANAG00000036321
Gene Symbol: MALT1
4 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 2

Ensembl ID : ENSANAG00000026513
Gene Symbol: MAPKAPK2
4 Cross references
240 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 5

Ensembl ID : ENSANAG00000023298
Gene Symbol: MAPKAPK5
4 Cross references
179 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSANAG00000022817
Gene Symbol: MKNK1
4 Cross references
168 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSANAG00000037709
Gene Symbol: MKNK2
4 Cross references
221 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSANAG00000021748
Gene Symbol: MCL1
3 Cross references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mdm2 Proto-Oncogene

Ensembl ID : ENSANAG00000027171
Gene Symbol: MDM2
3 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).